The US Food and Drug Administration (FDA) has approved EDDA Technology‘s new IQQA-Guide, an intra-operative precision 3D navigation system.
IQQA-Guide is designed to provide intra-operative precision 3D navigation for surgical procedures of thoracic, abdominal and pelvic soft organs.
The system, which is part of the IQQA platform and product suite, expands the IQQA precision 3D imaging analytics into the operating room.
IQQA anatomic models, which are extracted from multi-modality images, are used for on-the-fly 3D navigation to enable physicians to see organ surfaces and quantitatively reference anatomies of interest in 3D during surgery.
According to clinical studies, the IQQA-Guide may help reduce the use of intra-operative CT scans during image guided surgical procedures.
EDDA Technology president Dr Jianzhong Qian said: "With the latest FDA clearance, the IQQA platform now covers pre-operative planning, intra-operative navigation and monitoring, and post-operative assessment to complete the full cycle of imaging guided precision treatment.
"Powered by our precision 3D capabilities, IQQA-Guide may help facilitate the next generation of minimally invasive and robotic treatments in precision medicine."
The company’s IQQA-BodyImaging, which has treatment planning and follow-up assessment features, is used for liver, kidney and lung cancers.
It has been proven to provide significant time-saving and improved patient care in more than 22,000 cases.
The company will showcase the IQQA platform and product suite, as well as cloud-based services at RSNA 2015 in Chicago, US, from 29 November to 4 December.
EDDA Technology is involved in developing next generation computer-assisted solutions that will help in early detection and diagnosis, as well as in treatment planning, guidance, monitoring and follow-up.
Image: EDDA’s new intra-operative precision 3D navigation, IQQA-Guide. Photo: courtesy of EDDA Technology.